Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
ZURICH (Reuters) – Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand…
by October Gallery